China Health Industries Submits Hong Kong IPO Prospectus on June 30, Leads Pediatric CSO Market With 17% Share

According to Frost & Sullivan, on June 30, China Health Industries Holdings Inc. (Keli) submitted its prospectus to the Hong Kong Stock Exchange's main board for a second time, with China International Capital Corporation (CICC) serving as sole sponsor, formally launching its Hong Kong IPO process.

Keli holds exclusive distribution rights for Mommy Love and Eastan Static—two flagship pediatric over-the-counter drugs developed by South Korea's Hanmi Pharmaceutical Group. The company commands 17% market share in China's pediatric pharmaceutical marketing (CSO) sector, ranking first in the segment. Keli's distribution network spans 31 provinces and covers approximately 156,000 clinics, 367,000 pharmacies, and 1,700 hospitals, including 216 Class-A tertiary hospitals. For 2025, the company reported net profit of $32.96 million, up 50.7% year-over-year, with net margin improving to 10.8% from 7.1%. However, operating cash flow turned negative in 2024 and 2025, declining to -$7.07 million, while cash reserves fell from $58.45 million at end-2023 to $9.24 million at end-2025.